Preparing Performance Verification Documentation for Overseas Registration of Medical Dressings

Executive Summary

Performance verification documentation for overseas registration of medical dressings is not simply a factory release test report; it must be systematically organized according to the target country's regulatory framework, product classification, intended use, and registration pathway. Companies must first determine whether the product qualifies as a medical device in the target market, then establish the conformity assessment procedure based on risk classification. Only then can they decide which existing documents under NMPA, CE, FDA, or ISO 13485 can be reused directly and which must be regenerated according to local requirements.

Applicable Scenarios and Core Issues

Medical dressings are among the most common categories in medical device exports, but overseas registration requirements for performance verification documentation are not uniform. Companies typically encounter these issues when entering Southeast Asia, the Middle East, Latin America, or GHWP member states: What performance verification documents are needed? Can domestic test reports be used directly? Do biocompatibility tests need to be repeated? These questions directly affect registration timelines and costs.

The “performance verification documentation” discussed here does not refer to product performance parameters in the labeling, but rather the entire set of technical evidence submitted during registration to demonstrate that the product's safety and performance meet the target country's requirements. It includes not only laboratory test reports, but also test method bases, sample information, equipment details, acceptance criteria, stability data, and the logical connection with risk management and clinical evaluation.

Before preparing the documentation, companies must answer three questions: First, is the product within the regulatory scope of medical devices in the target country? Second, which risk class is the product assigned to? Third, should the product undergo premarket approval, self-declaration, or registration and filing? Without resolving these questions, any subsequent checklist may be directionally wrong.

Registration Determination Logic

Step 1: Determine Regulatory Status

Medical dressings may be classified as medical devices, drugs, disinfectants, or even ordinary daily necessities, depending on national regulations and product claims. For example, a dressing claiming to treat wound infection or promote healing may face drug regulation, while a dressing intended only to absorb exudate is usually a medical device. Companies should judge based on the target country's definition of a medical device and the intended use.

Step 2: Determine Risk Classification

The U.S. FDA typically classifies non-active wound dressings as Class I or Class II under 21 CFR 878.4010; under the EU MDR, they are often Class I or Class IIa; Southeast Asian countries often determine the registration pathway based on risk classification. Different risk classes correspond to significantly different requirements for performance verification, quality management system review, and clinical evidence.

Step 3: Evaluate Reusability of Existing Documents

For products that have already obtained NMPA registration, CE certificates, or FDA 510(k) clearance, their test reports, ISO 13485 system certificates, sterilization validation reports, and stability reports can serve as an important foundation, but they cannot be directly copied to other countries. Regulators have different requirements for laboratory qualifications, test standard versions, sample representativeness, expiration date coverage, and conformity with local pharmacopeias or national standards.

Step 4: Confirm Localization Requirements

In addition to the EU Authorized Representative, U.S. Agent, and Saudi Arabian Local Authorized Representative, most GHWP member states also require the designation of a local agent or registrant. The local agent is responsible for communicating with regulators, receiving adverse event reports, maintaining technical documents, and bearing corresponding legal obligations. The submission entity for performance verification documents, the need for notarized translations, and acceptance of foreign laboratory reports must be confirmed through the local agent.

Step 5: Plan Post-Market Maintenance

Performance verification documentation is not a one-time submission. Product changes, standard updates, certificate renewals, or recall events may trigger additional testing or technical document updates. Companies should incorporate post-market surveillance and performance tracking mechanisms into the document system at the design stage.

Documents and Evidence

Performance verification documentation for overseas registration of medical dressings generally covers the following aspects: physicochemical properties, biological evaluation, microbiology and sterilization validation, stability and packaging integrity, clinical evidence, and cross-validation with labeling.

Physicochemical Property Documentation

Includes test reports for dimensions, absorption rate, water vapor transmission rate, tensile strength, pH, heavy metal content, residue on ignition, fluorescent substances, etc. The reports must specify the test method, equipment, test date, sample batch number, and acceptance criteria.

Biocompatibility Documentation

Evaluate according to ISO 10993-1. Typically includes cytotoxicity, sensitization, irritation or intracutaneous reactivity. If the material contacts blood, additional tests such as systemic toxicity, genotoxicity, or implantation may be required. Pay attention to GLP qualifications and test standard versions.

Microbiology and Sterilization Documentation

Includes bioburden testing, sterility testing, sterilization process validation, sterilization expiration period, aeration period, and packaging integrity validation per ISO 11607. If the product is supplied sterile, a complete validation report must be provided.

Stability Documentation

Includes real-time aging and accelerated aging reports to verify shelf life, transport simulation testing, packaging integrity, and stability of performance indicators over the claimed shelf life. All claimed specifications should be covered.

Performance Verification Protocol and Report

Should clearly define the basis for each performance indicator, typically from product standards, national standards, industry standards, or monographs. Include sample information, statistical methods, deviation handling, and conclusions.

Clinical Evaluation Documentation

For the similar product pathway, literature search, similar product comparison, and equivalence demonstration are required. For products requiring clinical trials, provide the clinical trial protocol and report, or submit clinical evidence as required by local regulations.

Risk Management Documentation

Performance verification indicators should correspond to hazard analysis in the risk management file, demonstrating that risk control measures are effective. Technical documentation is usually part of the risk management report.

Labeling and Instructions Cross-Validation

Performance indicators, instructions for use, precautions, and expiration dates must be consistent across labels, instructions, and test reports.

Common Errors

• Directly using NMPA test reports without conducting a standard gap analysis. Chinese GB standards may differ from ISO, ASTM, or EN standards in test methods, sample preparation, and acceptance limits; regulators may not directly accept them.
• Ignoring target market requirements for laboratory qualifications. Some countries only accept reports from ISO 17025 accredited laboratories or locally recognized laboratories; reports from foreign non-accredited laboratories may be rejected.
• Insufficient sample representativeness. Registration test samples must cover all models and specifications, including typical, smallest, and complex-structure specifications; data from one model cannot represent the entire series.
• Insufficient stability study duration. To expedite registration, some companies only perform 6 or 9 months of accelerated aging without covering a claimed three-year shelf life; when asked for supplemental information, they cannot provide real-time aging data, leading to extended registration timelines.
• Biocompatibility tests not designed according to actual contact time and tissue type. For example, claiming wound contact but only performing surface device tests, missing tests corresponding to the conditions of use.
• Incomplete sterilization validation. Sterile dressings may provide only sterilization process parameters without sterilization dose audit, sterilized product performance validation, or residual data after packaging, requiring supplemental submission.
• Ignoring alignment between labeling and performance data. Claims such as “waterproof” or “breathable” are made without corresponding test data, leading to deletion of claims by local regulators or requests for retesting.
• Unclear local agent responsibilities. The company does not participate in submission, the local agent cannot answer regulatory questions, and technical document authorization letters and signatures are missing, preventing progress of the application.

Corporate Preparation Checklist

• Complete product attribute and classification assessment for the target country, outputting classification basis and risk class conclusion.
• Establish a master technical document list, organize existing NMPA, CE, FDA, and ISO 13485 documents, and mark items reusable versus items requiring additional work.
• Define the performance verification strategy, clarifying referenced standards, test items, and acceptance criteria; develop and approve the validation protocol.
• Select appropriate third-party laboratories with proper qualifications, and confirm report language, format, and notarization requirements.
• Prepare sample management records and batch information, ensuring model coverage, sample retention, and environmental conditions.
• Compile or update the risk management report, ensuring performance indicators are linked to risk analysis.
• Organize biocompatibility evaluation reports and material ingredient information; reassess if necessary.
• Complete sterilization validation and packaging integrity validation, providing the full set of reports.
• Develop a stability study protocol covering real-time and accelerated aging, including completion dates and contingency strategies.
• Prepare labeling and instructions for use drafts, verifying all performance claims against data sources.
• Identify the local agent or authorized representative, sign the authorization letter, and clearly define responsibilities.
• Establish post-market surveillance and adverse event reporting procedures, and prepare transition and renewal plans.

AIMEILI's Perspective

The most common misjudgment is assuming that test reports obtained in one mature market are “globally valid.” In reality, different countries have different requirements for product attributes, classification, standards, laboratory qualifications, language, and administrative approval processes. AIMEILI recommends conducting a complete regulatory gap analysis early in the project, producing a “target country requirements vs. existing evidence” comparison table, and then deciding which tests must be repeated. Stability, sterilization validation, and biocompatibility are the most frequent items requiring supplemental information, so arrange them in advance.

Reusable documents include ISO 13485 quality management system certificates, clinical literature based on international standards, physicochemical test methods compliant with international standards, and some biocompatibility data. Items that must be localized include language translations, labeling format, standard versions required by local regulations, local agent authorization documents, and technical document templates conforming to the country's pharmacopeia or registration format. Companies should pay special attention to managing local agents; the manufacturer should ideally retain control over certificates. Key milestones for changes and renewals should be set up with automatic reminders, and the registration certificate storage and updates should not be entirely delegated to third parties unfamiliar with the product language.

For multi-country registration, use a core technical document as the master file and treat target country differences as annexes. Companies can first prepare a core data package based on principles accepted across GHWP member states, then adjust modularly according to specific country requirements. This reduces redundant effort, lowers the risk of supplemental submissions caused by version confusion, and accelerates subsequent registration in new countries.

Frequently Asked Follow-ups

Is biocompatibility testing always required for overseas registration of medical dressings?

Most countries require biological evaluation according to ISO 10993 series standards, but the specific tests depend on contact duration, contact type, and material composition. If the product has been on the market for many years and there is sufficient similar-product contact data, some countries may allow exemption from certain tests through literature justification and risk management documentation. However, it is recommended to retain a complete biocompatibility evaluation report, as reviewers frequently request it.

Can NMPA test reports be submitted directly to overseas regulators?

In some cases, yes, provided the testing laboratory has internationally recognized qualifications and the test standards, sample information, and acceptance criteria align with the target country's requirements. Many countries do not accept test reports based solely on Chinese national standards, especially for microbiology, sterilization, and stability, where differences are significant. Companies should map each NMPA report against ISO/ASTM/EN standards, identify gaps, and decide whether to submit supplementary data or re-test.

How can performance verification documents be shared across multiple countries?

Establish a core technical document library with common data such as physicochemical properties, biocompatibility, sterilization validation, and stability, and create a difference file for each target country. When sharing test reports, verify that batch numbers match, report originals or certified copies meet notarization requirements, and if necessary, local agents issue declarations of conformity. Preparing documents in line with GHWP-recommended harmonization principles can improve reuse rates.

Further Reading

• How to Use ISO 13485 Certificates for Overseas Registration of Medical Dressings
• How to Determine the Product Classification of Medical Dressings for Overseas Registration
• How to Select a Local Agent for Overseas Registration of Implantable Products
• How to Divide the Responsibilities of Authorized Representatives for Implantable Products
• How to Divide the Responsibilities of Authorized Representatives for Laboratory Equipment
• Post-Market Surveillance for Overseas Registration of Laboratory Equipment

Content Review and Applicability Boundaries

Content Author: AIMEILI Regulatory Editorial Department. Professional Review: AIMEILI Medical Device International Registration Project Team. Source Principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary reference. Applicability Boundary: This article is for preliminary understanding, document preparation, and project planning, and does not replace the official requirements, testing conclusions, or legal opinions of the target country's regulatory authority.